Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

206 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Mittendorf EA, et al. Among authors: peoples ge. Ann Surg Oncol. 2006 Aug;13(8):1085-98. doi: 10.1245/ASO.2006.03.069. Epub 2006 Jul 24. Ann Surg Oncol. 2006. PMID: 16865596 Clinical Trial.
Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ. Linehan DC, et al. Among authors: peoples ge. J Immunol. 1995 Nov 1;155(9):4486-91. J Immunol. 1995. PMID: 7594611
In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour.
Linehan DC, Peoples GE, Hess DT, Summerhayes IC, Parikh AS, Goedegebuure PS, Eberlein TJ. Linehan DC, et al. Among authors: peoples ge. Surg Oncol. 1995 Feb;4(1):41-9. doi: 10.1016/s0960-7404(10)80030-1. Surg Oncol. 1995. PMID: 7780612
Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.
Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Peoples GE, et al. Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):432-6. doi: 10.1073/pnas.92.2.432. Proc Natl Acad Sci U S A. 1995. PMID: 7831305 Free PMC article.
TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers.
Peoples GE, Yoshino I, Douville CC, Andrews JV, Goedegebuure PS, Eberlein TJ. Peoples GE, et al. J Immunol. 1994 May 15;152(10):4993-9. J Immunol. 1994. PMID: 7909829
HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.
Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, Gazdar AF, Eberlein TJ. Yoshino I, et al. Among authors: peoples ge. Cancer Res. 1994 Jul 1;54(13):3387-90. Cancer Res. 1994. PMID: 7912166
Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R, Eberlein TJ. Yoshino I, et al. Among authors: peoples ge. J Immunol. 1994 Mar 1;152(5):2393-400. J Immunol. 1994. PMID: 8133050
T-cell recognition of ovarian cancer.
Peoples GE, Schoof DD, Andrews JV, Goedegebuure PS, Eberlein TJ. Peoples GE, et al. Surgery. 1993 Aug;114(2):227-34. Surgery. 1993. PMID: 8342128
Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides.
Peoples GE, Anderson BW, Fisk B, Kudelka AP, Wharton JT, Ioannides CG. Peoples GE, et al. Ann Surg Oncol. 1998 Dec;5(8):743-50. doi: 10.1007/BF02303486. Ann Surg Oncol. 1998. PMID: 9869522
Feasibility of breast conservation therapy in metachronous or synchronous bilateral breast cancer.
Heaton KM, Peoples GE, Singletary SE, Feig BW, Ross MI, Ames FC, Buchholz TA, Strom EA, McNeese MD, Hunt KK. Heaton KM, et al. Among authors: peoples ge. Ann Surg Oncol. 1999 Jan-Feb;6(1):102-8. doi: 10.1007/s10434-999-0102-8. Ann Surg Oncol. 1999. PMID: 10030422
206 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback